OUR TECHNOLOGY
Targeting the Wiskott-Aldrich-Syndrome Protein
BIMINI’s approach is based on a proprietary technology platform targeting the Wiskott–Aldrich Syndrome protein (WASp). The company has built a proprietary portfolio of first-in-class small-molecule WASp modulators, including both agonists and antagonists. This portfolio includes a proprietary WASp agonist, BM-011, licensed from the Institute of Oncology Research in Switzerland.
BIMINI’s portfolio is currently in the preclinical stage and has demonstrated potent activity across multiple oncology indications, including lymphomas and leukemias, as well as in autoimmune diseases. The company is now advancing its lead programs toward first-in-human clinical studies.
WASP 101
Wiskott–Aldrich Syndrome protein (WASp) is a cytosolic protein of 502 amino acids, predominantly expressed in non-erythroid hematopoietic cells. WASp is a key regulator of actin cytoskeleton dynamics through its interaction with the Arp2/3 complex, enabling efficient actin polymerization.
Through this central role, WASp critically controls lymphoid and myeloid cell proliferation, migration, receptor signaling, cytotoxic activity, and phagocytosis. Because of this multifaceted function in immune cell behavior, dysregulation of WASp is highly relevant in oncology—such as leukemia and lymphoma—as well as in autoimmune diseases including arthritis and colitis.
The Team
BIMINI’s management team consists of ambitious entrepreneurs with a solid scientific background who translate science into real-world impact.
Digvijay Gahtory PhD
CEO
Maurits van den Nieuwboer PhD
COO
Stephen Croke PhD
Lead R&D Scientist
Supervisory Board
BIMINI Biotech’s Supervisory Board consists of seasoned leaders in science, biotech, and business
Helmuth van Es PhD
Independent Board Director
Bioconsilium
Rob Mayfield
Chair of the Board
Libertatis Ergo Holding
Rouslan Michtchenko
Board Director
Torrey Pines Investment
Vasily Kazey PhD
Board Director
Torrey Pines Investment
Lieke Hamoen
Board Observer
InnovationQuarter Capital
Science and business advisors
BIMINI Biotech’s advisors consist of highly experienced professionals that support in business and science.
Prof F. Bertoni
Scientific Advisor
Institute of Oncology Research
Prof. N. Martin
Advisor Chemistry
Institute of Biology Leiden
Prof. M. Peeters
Advisor Clinical
University Hospital Antwerp
C. van den Brink
Advisor Legal
Axon Lawyers
H. Viëtor PhD, MD
Business Advisor
FFUND
Latest News
Keep up to date with the latests progression and achievement of BIMINI Biotech.
Dr. Helmuth van Es joins BIMINI Biotech as Independent Supervisory Board Member
Leiden, 6 January 2026 – BIMINI Biotech is pleased to announce the appointment of Dr. Helmuth van Es as an Independent Supervisory Board Member. Dr. van Es is a highly[…]
Read more
BIMINI Biotech raises a EUR3M seed round to advance first-in-class therapeutics for hematological cancers
Leiden, January 8th, 2025 – BIMINI Biotech, an innovative Leiden-based drug development company that develops novel therapeutics for hematological cancers, successfully closed a seed investment round of EUR 3 million.[…]
Read more
BIMINI welcomes Prof. Nathaniel Martin as advisor chemistry
BIMINI Biotech is happy to have Prof. Nathaniel Martin join the team as an advisor on chemistry, supporting the lead optimization. Prof. Martin is Professor of Biological Chemistry Institute of[…]
Read moreBIMINI Biotech is supported/funded by:
Contact us
For collaborations, partnerships, or general inquiries, contact BIMINI Biotech.
